Myriad Genetics (MYGN) Competitors $8.01 -0.07 (-0.87%) Closing price 04:00 PM EasternExtended Trading$8.02 +0.01 (+0.06%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MYGN vs. FOLD, LGND, DVAX, MNKD, BCRX, INVA, NVAX, CLDX, OPK, and GERNShould you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Amicus Therapeutics (FOLD), Ligand Pharmaceuticals (LGND), Dynavax Technologies (DVAX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Innoviva (INVA), Novavax (NVAX), Celldex Therapeutics (CLDX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. Myriad Genetics vs. Amicus Therapeutics Ligand Pharmaceuticals Dynavax Technologies MannKind BioCryst Pharmaceuticals Innoviva Novavax Celldex Therapeutics OPKO Health Geron Amicus Therapeutics (NASDAQ:FOLD) and Myriad Genetics (NASDAQ:MYGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, community ranking, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk & volatility, FOLD or MYGN? Amicus Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Does the MarketBeat Community favor FOLD or MYGN? Amicus Therapeutics received 55 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 72.98% of users gave Amicus Therapeutics an outperform vote while only 52.82% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes53272.98% Underperform Votes19727.02% Myriad GeneticsOutperform Votes47752.82% Underperform Votes42647.18% Is FOLD or MYGN more profitable? Amicus Therapeutics has a net margin of -10.62% compared to Myriad Genetics' net margin of -14.09%. Amicus Therapeutics' return on equity of 12.44% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-10.62% 12.44% 2.60% Myriad Genetics -14.09%-4.51%-3.07% Do institutionals & insiders have more ownership in FOLD or MYGN? 99.0% of Myriad Genetics shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 2.1% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to FOLD or MYGN? In the previous week, Myriad Genetics had 5 more articles in the media than Amicus Therapeutics. MarketBeat recorded 15 mentions for Myriad Genetics and 10 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.00 beat Myriad Genetics' score of 0.25 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate FOLD or MYGN? Amicus Therapeutics presently has a consensus target price of $16.75, suggesting a potential upside of 142.75%. Myriad Genetics has a consensus target price of $20.89, suggesting a potential upside of 160.83%. Given Myriad Genetics' higher probable upside, analysts plainly believe Myriad Genetics is more favorable than Amicus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Myriad Genetics 3 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.19 Which has better valuation & earnings, FOLD or MYGN? Amicus Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.30M4.01-$151.58M-$0.18-38.33Myriad Genetics$837.60M0.87-$263.30M-$1.41-5.68 SummaryAmicus Therapeutics beats Myriad Genetics on 12 of the 18 factors compared between the two stocks. Remove Ads Get Myriad Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYGN vs. The Competition Export to ExcelMetricMyriad GeneticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$731.39M$2.32B$5.33B$7.57BDividend YieldN/A0.78%5.11%4.33%P/E Ratio-6.166.1121.7317.81Price / Sales0.8747.32379.1494.58Price / CashN/A15.7538.1534.64Price / Book0.842.956.464.00Net Income-$263.30M-$65.73M$3.20B$247.23M7 Day Performance3.62%9.11%6.54%7.26%1 Month Performance-20.46%-14.92%-8.55%-6.26%1 Year Performance-58.22%-18.74%10.33%-0.18% Myriad Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYGNMyriad Genetics3.823 of 5 stars$8.01-0.9%$20.89+160.8%-58.7%$731.39M$837.60M-6.162,700Gap DownFOLDAmicus Therapeutics4.0285 of 5 stars$7.15-4.7%$16.75+134.3%-37.1%$2.20B$528.30M-39.72480Positive NewsGap DownLGNDLigand Pharmaceuticals4.3435 of 5 stars$99.41-0.2%$147.00+47.9%+31.0%$1.91B$167.13M39.6180Analyst UpgradeNews CoveragePositive NewsGap DownDVAXDynavax Technologies4.3787 of 5 stars$12.49-1.3%$21.50+72.1%-3.4%$1.55B$277.25M69.39350Positive NewsGap DownMNKDMannKind2.2584 of 5 stars$4.69-1.1%$9.21+96.5%+11.6%$1.43B$285.50M67.00400BCRXBioCryst Pharmaceuticals4.1287 of 5 stars$6.79-0.6%$15.57+129.3%+47.6%$1.42B$450.71M-11.13530Gap DownINVAInnoviva4.3495 of 5 stars$17.51-1.2%$55.00+214.1%+22.9%$1.10B$358.71M25.38100Analyst UpgradeNews CoveragePositive NewsNVAXNovavax3.6164 of 5 stars$6.54+4.8%$18.00+175.2%+49.8%$1.05B$682.16M-2.891,990CLDXCelldex Therapeutics2.3254 of 5 stars$15.73-0.3%$54.33+245.4%-54.7%$1.04B$7.02M-6.12150Positive NewsOPKOPKO Health4.1159 of 5 stars$1.53-1.3%$2.75+79.7%+15.4%$1.03B$713.14M-8.053,930Options VolumeGERNGeron3.7691 of 5 stars$1.41+2.2%$5.75+307.8%-63.7%$898.04M$76.99M-4.4170Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies FOLD Alternatives LGND Alternatives DVAX Alternatives MNKD Alternatives BCRX Alternatives INVA Alternatives NVAX Alternatives CLDX Alternatives OPK Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYGN) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Myriad Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MYGN Stock Free MYGN Stock Alerts